Compare Ascendis Pharma A/S (ASND) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Credo Technology Group Holding Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Credo Technology Group Holding Ltd trades at $251.35 (market cap $48.07B). The key difference: Credo Technology Group Holding Ltd is far larger — about 2.7× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | CRDO | |
|---|---|---|
Market Cap | $17.74B | $48.07B |
Sector | Health | Technology |
52-Week High | $277.18 | $302.52 |
52-Week Low | $163.32 | $87.81 |
Enterprise Value | $18.11B | $46.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CRDO trades at $257.79, down 2.96% today but maintains strong bullish momentum with analyst consensus at 'Buy' (86.7% of 15 analysts). The stock shows robust fundamentals with 35.37% net income margin and triple-digit revenue growth projections for 2026. Recent earnings consistently beat expectations, and technical indicators suggest bullish momentum with support at $258 and resistance at $276.
Outlook remains positive given AI infrastructure demand and strong financial performance, though elevated valuations (P/E 102.7) and customer concentration risks warrant caution. The consensus price target of $273.33 implies 6% upside potential from current levels, supported by institutional optimism and expanding market opportunities in high-speed connectivity solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
